Qiagen (NYSE:QGEN) Stock Rating Lowered by Robert W. Baird

Qiagen (NYSE:QGEN) was downgraded by research analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a research note issued to investors on Wednesday,Briefing.com Automated Import reports. They presently have a $42.00 price objective on the stock, down from their previous price objective of $52.00. Robert W. Baird’s price target would indicate a potential upside of 4.87% from the stock’s current price.

Several other brokerages have also weighed in on QGEN. Jefferies Financial Group restated a “buy” rating and issued a $52.50 price objective (up previously from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Morgan Stanley reaffirmed an “equal weight” rating and set a $46.67 target price (down from $48.61) on shares of Qiagen in a report on Monday, January 6th. Finally, UBS Group reduced their target price on Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Six investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $47.71.

Qiagen Stock Up 0.5 %

Shares of NYSE:QGEN opened at $40.05 on Wednesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. Qiagen has a 1 year low of $39.27 and a 1 year high of $49.30. The stock has a market capitalization of $8.89 billion, a P/E ratio of 111.52, a PEG ratio of 2.59 and a beta of 0.36. The stock has a 50-day simple moving average of $43.48 and a 200-day simple moving average of $43.16.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Equities analysts forecast that Qiagen will post 2.26 earnings per share for the current year.

Institutional Investors Weigh In On Qiagen

Several hedge funds have recently bought and sold shares of the business. Geneos Wealth Management Inc. increased its position in Qiagen by 41.5% in the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock worth $38,000 after purchasing an additional 251 shares during the last quarter. CWM LLC increased its position in Qiagen by 11.5% in the 3rd quarter. CWM LLC now owns 2,792 shares of the company’s stock worth $127,000 after purchasing an additional 287 shares during the last quarter. Zurich Insurance Group Ltd FI increased its position in Qiagen by 5.7% in the 3rd quarter. Zurich Insurance Group Ltd FI now owns 5,291 shares of the company’s stock worth $239,000 after purchasing an additional 287 shares during the last quarter. National Bank of Canada FI increased its position in Qiagen by 1.2% in the 3rd quarter. National Bank of Canada FI now owns 25,636 shares of the company’s stock worth $1,155,000 after purchasing an additional 308 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its position in Qiagen by 3.6% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company’s stock worth $438,000 after purchasing an additional 341 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.